Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acromesomelic dysplasia, Hunter-Thomson type is an autosomal recessively inherited form of acromesomelic dysplasia characterized by severe dwarfism (adult height approximately 120 cm) with abnormalities limited to the limbs (affecting the lower limbs more than upper limbs, with middle and distal segments being the most affected), severe shortening, absence or fusion of tubular bones of hands and feet and large joint dislocations. As seen in acromesomelic dysplasia, Grebe type and acromesomelic dysplasia, Maroteaux type, facial features and intelligence are normal.
Features include always present findings: Fibular hypoplasia. 17 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 4 | Short foot, Severe short-limb dwarfism, Shortening of all middle phalanges of the fingers |
Bones and joints |
GDF5 encodes growth differentiation factor 5 (501 aa). Growth factor involved in bone and cartilage formation. During cartilage development regulates differentiation of chondrogenic tissue through two pathways. Highest expression in Cells Cultured fibroblasts (7.0 TPM) and Minor Salivary Gland (4.0 TPM).
Acromesomelic dysplasia 2C, Hunter-Thompson type is associated with mutations in the GDF5 gene on chromosome 20.
The GDF5 protein participates in Signaling by BMP pathway.
GDF5 is classified as a druggable target (Druggable Genome, Growth Factor, and Transcription Factor categories) with score 0.0.
Genetic testing for GDF5 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for acromesomelic dysplasia 2C, Hunter-Thompson type.
2 publications have been identified in PubMed for acromesomelic dysplasia 2C, Hunter-Thompson type. Research spans Case Report / Case Series (50%) and Epidemiology / Natural History (50%).
Li X (2026). [PMID: 41507789](https://pubmed.ncbi.nlm.nih.gov/41507789/). *BMC genomics*. [Epidemiology / Natural History]
Abdelrazek IM (2024). [PMID: 39441036](https://pubmed.ncbi.nlm.nih.gov/39441036/). *Molecular genetics & genomic medicine*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acromesomelic dysplasia 2C, Hunter-Thompson type
2 |
Distal femoral bowing, Abnormally shaped carpal bones |
Growth and development | 1 | Severe short-limb dwarfism |